Industry Newsgenome editingex vivo therapybeam therapeuticssickle cell disease
Beam Therapeutics Receives Bullish Analyst Reaffirmation
5.0
H.C. Wainwright analyst Patrick Trucchio reaffirmed a Buy on Beam Therapeutics on December 9, setting an $80 target that implies about 201% upside. He cites BEACON trial data showing risto-cel's ability to change hemoglobin, resolve anemia and prevent vaso-occlusive crises, and notes a scalable vein-to-vein manufacturing process. As of December 19 the consensus median target is $43 with 11 of 13 analysts rating Buy.
Key Points
- 1Reaffirms Buy rating with $80 target, implying roughly 201% upside from current levels
- 2Highlights BEACON trial showing risto-cel alters hemoglobin, cures anemia, prevents vaso-occlusive crises
- 3Indicates scalable vein-to-vein manufacturing could give Beam competitive edge in ex vivo hematology commercialization
Scoring Rationale
Actionable analyst update supported by BEACON trial data, but limited to company-level news and single-source emphasis.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
